Zilovertamab Vedotin 在血液恶性肿瘤患者中的序贯群体药代动力学模型及其向儿科人群的外推
本研究基于一项 zilovertamab vedotin 治疗血液恶性肿瘤的 I 期研究数据,采用简化 ADC 群体药代动力学建模策略,构建了包含 acMMAE、总单克隆抗体和游离 MMAE 的三分析物模型,并将模型外推至儿科人群。模型对成人数据拟合良好,MMAE 通过载荷去偶联和 acMMAE 完全蛋白水解降解两种途径释放;儿科模拟支持基于体重给药方案,使 acMMAE 暴露与成人匹配且毒性 MMAE 浓度不高于成人。
要点
- 三分析物模型可同时描述 acMMAE、总抗体和游离 MMAE 的 PK 特征。
- MMAE 释放包括去偶联(即刻释放)和蛋白水解降解(延迟释放)两条途径。
- 儿科按体重给药可匹配成人 acMMAE 暴露且游离 MMAE 不高于成人。
核心结论
- 总单抗、acMMAE 和游离 MMAE 三分析物模型对数据拟合良好。
- 儿科人群在相同体重给药方案下可匹配成人 acMMAE 暴露,且毒性 MMAE 浓度不高于成人。
研究设计与样本
- 基于 zilovertamab vedotin 治疗血液恶性肿瘤的 I 期研究数据。
- 采用 Gibiansky 简化 ADC popPK 模型的分步建模策略。
- 建模分析物为 acMMAE、总单克隆抗体和游离 MMAE。
- 使用清除率成熟函数并考虑体重相关 PK 变化外推至儿科人群。
主要发现
- 简化模型为拟合成人 acMMAE、总单抗和游离 MMAE 数据提供了良好结构。
- MMAE 通过载荷去偶联和 acMMAE 完全蛋白水解降解两条途径释放。
- 去偶联与 MMAE 即刻释放相关,蛋白水解清除导致 MMAE 释放延迟。
关键数值与推荐
- 儿科给药策略基于模型外推模拟,已在美国和欧盟获批。
临床怎么用
- 该模型支持 zilovertamab vedotin 在儿科人群采用基于体重的给药方案。
- 临床可依据模型模拟结果评估儿科给药后 acMMAE 暴露与游离 MMAE 安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Recently a number of antibody-drug conjugate (ADC) pharmacometric models have been reported in the literature, describing one or two ADC-related analytes. The objective of this analysis was to build a population pharmacokinetic (popPK) three-analyte ADC model to describe efficacy and safety of zilovertamab vedotin, an ROR1-targeting ADC conjugated to monomethyl auristatin E (MMAE). METHODS: Data from a phase 1 study of zilovertamab vedotin in subjects with hematologic malignancies was used in a stepwise ADC modeling strategy based on the simplified ADC popPK model proposed by Gibiansky. This choice provided opportunity to model three analytes: conjugated monomethyl auristatin E (acMMAE), total monoclonal antibody (total mAb), and free MMAE. The model was extrapolated to the pediatric population using a clearance maturation function and accounting for weight dependent pharmacokinetic (PK) changes. RESULTS: The simplified model provided a good structure to fit the adult acMMAE, total mAb, and free MMAE data. Analysis showed that MMAE was released through deconjugation of the payload and full proteolytic degradation of the acMMAE. Deconjugation was associated with an immediate release of MMAE, proteolytic clearance introduced a delay in the release of MMAE. Simulation of the model extrapolated to the pediatric population was the basis for pediatric dosing strategies for zilovertamab vedotin that were approved in the United States and European Union. CONCLUSIONS: The total mAb, acMMAE, and free MMAE model showed a good fit to the data. The pediatric population can match the acMMAE adult exposure at the same weight-based dose regimen without concerns that the toxic MMAE concentration will reach higher levels than found in adults.
引用
- Zweers TJ, Lommerse J, van Maanen E, et al. A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population. Clin Pharmacokinet. 2024. PMID: 39438409. doi:10.1007/s40262-024-01429-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。